Consumer
Biogen is acquiring RayThera for approximately $1 billion to bolster its immunology pipeline. The deal signals a strategic pivot away from Biogen's neurology-heavy identity but adds pipeline risk and cash outflow at a time of modest 2.2% revenue growth.
0 reads·0 theses
The AngleGenuinely two-sided
Bull case
Immunology represents a large, underpenetrated market for Biogen, and a successful RayThera asset could add a non-neurological revenue leg that justifies a re-rating of the company's forward multiple beyond its current low-growth valuation.
Bear case
With only 13.1% net margins and $8.79 diluted EPS, a $1B upfront cash outlay carries real dilution risk, and Biogen's history of costly pipeline bets (including the Aduhelm controversy) raises legitimate questions about capital allocation discipline.
Both sides — weigh them yourself